New Data Shared at AACR-IASLC
As part of Myriad’s ongoing commitment to advance the science of lung cancer care, we shared exciting new data at this year’s AACR-IASLC International Joint Conference in San Diego. Here is a quick recap of the poster presentation targeted at improving patient outcomes in early stage lung cancer.
Background:
Recurrence and lung cancer mortality in resected, early stage non-small cell lung cancer (NSCLC) are likely due to the presence of micro-metastatic disease not detected during surgery or the pre-surgical assessment. The aim of this study was to validate cell cycle progression gene expression (CCP Score) and the molecular Prognostic Score as predictors of 5-year distant recurrence-free survival in a cohort of surgically treated lung adenocarcinomas without adjuvant treatment.
